Cullinan Oncology LLC (CGEM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cullinan Oncology LLC (CGEM) has a cash flow conversion efficiency ratio of -0.126x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.05 Million) by net assets ($366.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CGEM market cap for the company's overall valuation and market capitalisation.
Cullinan Oncology LLC - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Cullinan Oncology LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cullinan Oncology LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cullinan Oncology LLC ranked by their cash flow conversion efficiency. Explore CGEM cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GrocerIQ, Inc
NYSE:WPFHD
|
N/A |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
0.011x |
|
Swedish Logistic Property AB Series B
ST:SLP-B
|
0.013x |
|
Domino's Pizza Enterprises Limited
F:HQX
|
0.082x |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH
|
0.050x |
|
Shanghai Haixin Group Co Ltd A
SHG:600851
|
0.014x |
|
Tianjin Printronics Circuit Corp
SHE:002134
|
0.043x |
|
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
|
0.110x |
Annual Cash Flow Conversion Efficiency for Cullinan Oncology LLC (2013–2025)
The table below shows the annual cash flow conversion efficiency of Cullinan Oncology LLC from 2013 to 2025. View current stock price of Cullinan Oncology LLC for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $408.73 Million | $-175.75 Million | -0.430x | -74.69% |
| 2024-12-31 | $590.33 Million | $-145.30 Million | -0.246x | +16.80% |
| 2023-12-31 | $453.89 Million | $-134.28 Million | -0.296x | -24.96% |
| 2022-12-31 | $535.03 Million | $-126.66 Million | -0.237x | -131.86% |
| 2021-12-31 | $425.37 Million | $-43.43 Million | -0.102x | +31.30% |
| 2020-12-31 | $200.31 Million | $-29.77 Million | -0.149x | -128.38% |
| 2019-12-31 | $-39.91 Million | $-20.90 Million | 0.524x | -20.20% |
| 2018-12-31 | $-20.65 Million | $-13.55 Million | 0.656x | +64.77% |
| 2016-12-31 | $-574.85K | $-228.91K | 0.398x | +1962.80% |
| 2015-12-31 | $-1.24 Million | $-24.03K | 0.019x | -76.10% |
| 2014-12-31 | $-1.14 Million | $-91.72K | 0.081x | -88.70% |
| 2013-12-31 | $-1.00 Million | $-718.41K | 0.715x | -- |
About Cullinan Oncology LLC
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049,… Read more